Evidence map›Paper›PMID 41256653›Full record

ArticlebioRxiv : the preprint server for biology2025

A Covalent PFKL Activator Suppresses Tumor Growth.

Xiaoding Jiang, Eric M Lynch, Congcong Lyu, Crystal Wilson, Lauren E Salay, Scott Lyons, Mu-Jie Lu, Shuangyu Luo, Gibae Kim, Hsin-Ru Chan and 5 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors.

Xiaoding JiangDepartment of Chemistry, The University of Texas at Austin, Austin, Texas 78712, USA.
Eric M LynchDepartment of Biochemistry, University of Washington, Seattle, Washington 98195, USA.
Congcong LyuDepartment of Molecular Biosciences, The University of Texas at Austin, Austin, Texas 78712, USA.
Crystal WilsonDepartment of Molecular Biosciences, The University of Texas at Austin, Austin, Texas 78712, USA.
Lauren E SalayDepartment of Biochemistry, University of Washington, Seattle, Washington 98195, USA.
Scott LyonsDepartment of Molecular Biosciences, The University of Texas at Austin, Austin, Texas 78712, USA.
Mu-Jie LuDepartment of Molecular Biosciences, The University of Texas at Austin, Austin, Texas 78712, USA.
Shuangyu LuoDepartment of Chemistry, The University of Texas at Austin, Austin, Texas 78712, USA.
Gibae KimDepartment of Chemistry, The University of Texas at Austin, Austin, Texas 78712, USA.
Hsin-Ru ChanDepartment of Molecular Biosciences, The University of Texas at Austin, Austin, Texas 78712, USA.
Wes WolfeDepartment of Chemistry, The University of Texas at Austin, Austin, Texas 78712, USA.
Yi-Chih LinDepartment of Chemistry, The University of Texas at Austin, Austin, Texas 78712, USA.
Justin M KollmanDepartment of Biochemistry, University of Washington, Seattle, Washington 98195, USA.
Xiaolu A CambronneDepartment of Molecular Biosciences, The University of Texas at Austin, Austin, Texas 78712, USA.ORCID 0000-0002-3547-448X
Ku-Lung HsuDepartment of Chemistry, The University of Texas at Austin, Austin, Texas 78712, USA.ORCID 0000-0001-5620-3972

Funding

Endocannabinoid Biosynthesis in Inflammation and PainR01DA043571 · NIDA · UNIVERSITY OF VIRGINIA · PI Ku-Lung Hsu · 2017 to 2026
$3.5M
Structure and function of metabolic enzyme assembliesR35GM149542 · NIGMS · UNIVERSITY OF WASHINGTON · PI Justin M Kollman · 2023 to 2026
$2.2M
Mitochondrial NAD+ in Acute Myeloid LeukemiasR01CA272490 · NCI · UNIVERSITY OF TEXAS AT AUSTIN · PI Xiaolu Ang Cambronne · 2023 to 2026
$2.1M
Acquisition of a high resolution, high throughput cryo-electron microscopeS10OD023476 · OD · UNIVERSITY OF WASHINGTON · PI KOLLMAN, JUSTIN M · 2017 to 2017
$2.0M
Defining and targeting substrate specificity of protein tyrosine phosphatasesR01GM144472 · NIGMS · UNIVERSITY OF VIRGINIA · PI HSU, KU-LUNG · 2022 to 2025
$1.6M
Chemical proteomic investigation of lipid kinase specificity and druggabilityR01AI169412 · NIAID · UNIVERSITY OF VIRGINIA · PI Ku-Lung Hsu · 2023 to 2026
$1.5M
Localized Real-time Sensors for Metabolic SignalingR35GM152218 · NIGMS · UNIVERSITY OF TEXAS AT AUSTIN · PI Xiaolu Ang Cambronne · 2024 to 2026
$1.1M
Investigating the Structure and Regulation of PFKF32GM154453 · NIGMS · UNIVERSITY OF WASHINGTON · PI Lauren Salay · 2024 to 2026
$241k
NCI NIH HHS R01 CA272490NIAID NIH HHS R01 AI169412NIDA NIH HHS R01 DA043571NIGMS NIH HHS F32 GM154453NIGMS NIH HHS R01 GM144472NIGMS NIH HHS R35 GM149542NIGMS NIH HHS R35 GM152218NIH HHS S10 OD023476
6 · The paper itself

Abstract

Glycolysis fuels vital cellular functions and its dysregulation is implicated in cancer, neurodegeneration, antibiotic resistance and diabetes. The glycolytic dependency of cancer, known as the Warburg effect, presents a key vulnerability for developing targeted anticancer agents but remains challenging due to metabolic heterogeneity and resistance. Here, we developed a first-in-class covalent phosphofructokinase-1 liver type (PFKL) activator that induces metabolic imbalance coupled to delivery of a cytotoxic payload to cancer cells

Identifiers

PMID41256653
PMCPMC12621983

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.